Analysts Set Expectations for eFFECTOR Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:EFTR)

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRGet Rating) – Stock analysts at Cantor Fitzgerald increased their FY2022 EPS estimates for eFFECTOR Therapeutics in a research report issued on Wednesday, May 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn ($0.54) per share for the year, up from their previous estimate of ($0.81).

A number of other research firms have also issued reports on EFTR. Stifel Nicolaus lowered eFFECTOR Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $20.00 to $6.20 in a research note on Tuesday, January 25th. JMP Securities reiterated a “buy” rating and issued a $8.00 target price on shares of eFFECTOR Therapeutics in a research note on Monday, April 11th. Finally, Credit Suisse Group lowered their target price on eFFECTOR Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Thursday, March 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $19.64.

EFTR stock opened at $1.94 on Friday. The company has a current ratio of 13.30, a quick ratio of 13.30 and a debt-to-equity ratio of 1.09. eFFECTOR Therapeutics has a 1 year low of $1.94 and a 1 year high of $40.42. The stock has a 50-day simple moving average of $3.71 and a 200-day simple moving average of $5.91.

eFFECTOR Therapeutics (NASDAQ:EFTRGet Rating) last announced its quarterly earnings results on Wednesday, March 16th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.69. The firm had revenue of $0.31 million for the quarter.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SR One Capital Management LP acquired a new stake in eFFECTOR Therapeutics during the 4th quarter valued at approximately $56,487,000. Abingworth LLP acquired a new stake in eFFECTOR Therapeutics during the 3rd quarter valued at approximately $67,027,000. Sectoral Asset Management Inc acquired a new stake in eFFECTOR Therapeutics during the 3rd quarter valued at approximately $40,503,000. OUP Management Co. LLC acquired a new stake in eFFECTOR Therapeutics during the 4th quarter valued at approximately $8,493,000. Finally, Parallel Advisors LLC acquired a new stake in eFFECTOR Therapeutics during the 1st quarter valued at approximately $2,744,000. Hedge funds and other institutional investors own 51.71% of the company’s stock.

eFFECTOR Therapeutics Company Profile (Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

Read More

Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.